Compare · AEMD vs WST
AEMD vs WST
Side-by-side comparison of Aethlon Medical Inc. (AEMD) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AEMD and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $25.31B, about 14844.2x AEMD ($1.7M).
- Over the past year, AEMD is down 99.5% and WST is up 70.4% - WST leads by 169.9 points.
- AEMD has been more active in the news (11 items in the past 4 weeks vs 5 for WST).
- WST has more recent analyst coverage (18 ratings vs 2 for AEMD).
- Company
- Aethlon Medical Inc.
- West Pharmaceutical Services Inc.
- Price
- $0.67-1.12%
- $358.18-1.11%
- Market cap
- $1.7M
- $25.31B
- 1M return
- -65.20%
- +8.72%
- 1Y return
- -99.49%
- +70.45%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 5
- Recent ratings
- 2
- 18
Aethlon Medical Inc.
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest AEMD
- Presenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live stream
- Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
- Aethlon Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B3 filed by Aethlon Medical Inc.
- SEC Form EFFECT filed by Aethlon Medical Inc.
- Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
- Director Shah Chetan covered exercise/tax liability with 2,182 shares, decreasing direct ownership by 9% to 20,840 units (SEC Form 4) (withholding obligation)
- Director Gikakis Nicolas covered exercise/tax liability with 2,182 shares, decreasing direct ownership by 10% to 20,663 units (SEC Form 4) (tax liability)
- Director Broenniman Edward G covered exercise/tax liability with 1,091 shares, decreasing direct ownership by 5% to 22,363 units (SEC Form 4) (for withholding tax)
- Amendment: SEC Form S-1/A filed by Aethlon Medical Inc.
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits